- Home
- CTSO vs CHCI Comparison
CTSO vs CHCI Comparison
Compare CTSO & CHCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- CHCI
- Stock Information
- Founded
- CTSO 1997
- CHCI 1985
- Country
- CTSO United States
- CHCI United States
- Employees
- CTSO N/A
- CHCI N/A
- Industry
- CTSO Medical/Dental Instruments
- CHCI Building operators
- Sector
- CTSO Health Care
- CHCI Real Estate
- Exchange
- CTSO Nasdaq
- CHCI Nasdaq
- Market Cap
- CTSO 61.3M
- CHCI 68.9M
- IPO Year
- CTSO N/A
- CHCI 2004
- Fundamental
- Price
- CTSO $1.03
- CHCI $10.45
- Analyst Decision
- CTSO Strong Buy
- CHCI
- Analyst Count
- CTSO 3
- CHCI 0
- Target Price
- CTSO $4.67
- CHCI N/A
- AVG Volume (30 Days)
- CTSO 74.6K
- CHCI 61.5K
- Earning Date
- CTSO 05-08-2025
- CHCI 05-13-2025
- Dividend Yield
- CTSO N/A
- CHCI N/A
- EPS Growth
- CTSO N/A
- CHCI 83.12
- EPS
- CTSO N/A
- CHCI 1.41
- Revenue
- CTSO $35,594,520.00
- CHCI $51,294,000.00
- Revenue This Year
- CTSO $18.72
- CHCI N/A
- Revenue Next Year
- CTSO $19.75
- CHCI N/A
- P/E Ratio
- CTSO N/A
- CHCI $7.41
- Revenue Growth
- CTSO 14.51
- CHCI 14.70
- 52 Week Low
- CTSO $0.70
- CHCI $5.90
- 52 Week High
- CTSO $1.61
- CHCI $14.48
- Technical
- Relative Strength Index (RSI)
- CTSO 53.19
- CHCI 64.30
- Support Level
- CTSO $0.93
- CHCI $9.16
- Resistance Level
- CTSO $1.07
- CHCI $9.15
- Average True Range (ATR)
- CTSO 0.06
- CHCI 0.86
- MACD
- CTSO 0.01
- CHCI 0.11
- Stochastic Oscillator
- CTSO 71.43
- CHCI 90.27
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About CHCI Comstock Holding Companies Inc.
Comstock Holding Co Inc is a developer and manager of mixed-use and transit-oriented properties with operations that are majorly focused on the Washington, D.C. metropolitan area. It provides a range of services such as asset management, property management, development and construction management, and other real estate-related services to its asset-owning clients, composed predominantly of institutional real estate investors, high net worth family offices, financial institutions, and governmental bodies seeking to enhance their surrounding communities by developing real estate through public-private partnerships.